AIRLINK 189.36 Increased By ▲ 1.33 (0.71%)
BOP 11.10 Decreased By ▼ -0.76 (-6.41%)
CNERGY 7.28 Decreased By ▼ -0.26 (-3.45%)
FCCL 36.65 Decreased By ▼ -1.14 (-3.02%)
FFL 14.95 Decreased By ▼ -0.29 (-1.9%)
FLYNG 26.19 Increased By ▲ 0.66 (2.59%)
HUBC 130.89 Increased By ▲ 0.74 (0.57%)
HUMNL 13.47 Decreased By ▼ -0.14 (-1.03%)
KEL 4.28 Decreased By ▼ -0.07 (-1.61%)
KOSM 6.08 Decreased By ▼ -0.09 (-1.46%)
MLCF 45.94 Increased By ▲ 0.26 (0.57%)
OGDC 201.86 Decreased By ▼ -4.57 (-2.21%)
PACE 6.12 Decreased By ▼ -0.26 (-4.08%)
PAEL 38.36 Decreased By ▼ -1.95 (-4.84%)
PIAHCLA 16.73 Decreased By ▼ -0.22 (-1.3%)
PIBTL 7.94 Decreased By ▼ -0.09 (-1.12%)
POWER 9.86 Decreased By ▼ -0.17 (-1.69%)
PPL 173.46 Decreased By ▼ -5.38 (-3.01%)
PRL 34.73 Decreased By ▼ -1.63 (-4.48%)
PTC 23.95 Decreased By ▼ -0.44 (-1.8%)
SEARL 101.74 Decreased By ▼ -1.42 (-1.38%)
SILK 1.07 No Change ▼ 0.00 (0%)
SSGC 32.70 Decreased By ▼ -3.54 (-9.77%)
SYM 17.93 Decreased By ▼ -0.30 (-1.65%)
TELE 8.14 Decreased By ▼ -0.24 (-2.86%)
TPLP 12.02 Decreased By ▼ -0.14 (-1.15%)
TRG 67.40 Increased By ▲ 0.07 (0.1%)
WAVESAPP 11.80 Decreased By ▼ -0.21 (-1.75%)
WTL 1.52 Decreased By ▼ -0.05 (-3.18%)
YOUW 3.90 Increased By ▲ 0.01 (0.26%)
BR100 11,819 Decreased By -87.9 (-0.74%)
BR30 35,000 Decreased By -554.1 (-1.56%)
KSE100 112,085 Decreased By -478.8 (-0.43%)
KSE30 34,946 Decreased By -148 (-0.42%)
World

Moderna completes filing process for full approval of COVID-19 vaccine

  • Moderna's completed submission includes data from a late-stage study that showed 93% vaccine efficacy
Published August 25, 2021

Moderna Inc has completed the real-time review process needed for a full approval for its COVID-19 vaccine in people aged 18 years and above, the company said on Wednesday.

The news comes within days of US regulators granting full approval to Pfizer Inc/BioNTech SE's COVID-19 vaccine, developed with the same mRNA technology as Moderna's.

Messenger RNA (mRNA) vaccines prompt the human body to make a protein that is part of the pathogen, triggering an immune response.

US health officials expect full approval for COVID-19 vaccines will help win over vaccine skeptics and prompt more state and local governments, as well as private employers, to impose vaccine mandates.

Moderna's completed submission includes data from a late-stage study that showed 93% vaccine efficacy, even through six months after administration of the second dose, the company said in a statement.

As part of the submission, Moderna has requested a priority review designation for its vaccine, currently available in the United States for people aged 18 and older under an emergency use authorization (EUA) granted by the FDA in December.

So far, the company has released more than 300 million doses of the vaccine to the US government.

Comments

Comments are closed.